Galapagos appoints Michele Manto as Chief Commercial Officer
January 23 2020 - 4:01PM
Galapagos appoints Michele Manto as Chief Commercial Officer
Galapagos is preparing to deliver its first
medicine to patients
Mechelen, Belgium, 23 January 2020; 22.01 CET
– Galapagos NV (Euronext & NASDAQ: GLPG) announced today
that Michele Manto was appointed Chief Commercial Officer,
effective 1 January 2020. He served as Senior Vice President
Commercial Operations and in his new role will become a member of
the Executive Committee. Since joining Galapagos in September 2017,
he has built a strong commercial team from the ground up. His
appointment comes at a pivotal time in Galapagos’ history, as the
company prepares for the launch later this year of filgotinib, its
JAK1 inhibitor currently in the registration process for rheumatoid
arthritis. Filgotinib is Galapagos’ first medicine that is
anticipated to reach the market.
Previously, Michele held various commercial
leadership roles at AbbVie, most recently as General Manager,
Global Marketing Rheumatology and as General Manager in the
Netherlands. Prior to this, he led AbbVie’s commercial activities
and launches in inflammation in Germany and other European
countries. He started his professional career as a management and
strategy consultant at McKinsey & Company and holds an MBA from
INSEAD.
Commenting, Michele says: “Developing commercial operations from
scratch in an organization rooted in pioneering R&D has been an
inspiring journey. As we work towards our first product launch this
year, we will expand our team and capabilities to bring Galapagos
science to patients and society. I am in the fortunate position of
working for a company that is distinctively pioneering, focusing on
developing innovative medicines that will improve people’s
lives.”
CEO Onno van de Stolpe, who founded the company in 1999 adds:
“Michele’s promotion to the Executive Committee reflects the
significant contribution he has already made to Galapagos’ success.
He has an in-depth knowledge of our industry, a patient-focused
approach, and an impressive ability to anticipate and respond
swiftly to business challenges and opportunities. The Executive
Committee looks forward to Michele’s contributions as we enter the
next important and exciting phase of our commercial
development.”
Galapagos is working with its commercial partner, Gilead
Sciences, to prepare the launch of filgotinib in 2020.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops
small molecule medicines with novel modes of action, several of
which show promising patient results and are currently in
late-stage development in multiple diseases. Our pipeline comprises
Phase 3 through to discovery programs in inflammation, fibrosis,
osteoarthritis and other indications. Our ambition is to become a
leading global biopharmaceutical company focused on the discovery,
development and commercialization of innovative medicines. More
information at www.glpg.com.
Contact
Investors: Elizabeth Goodwin VP Investor Relations +1 781
460 1784
Sofie Van Gijsel Director Investor Relations +32 485 19 14 15
ir@glpg.com
Media: Carmen Vroonen Senior Director Communications
& Public Affairs +32 473 824 874
Evelyn Fox Director Communications +31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements with respect to Galapagos, including statements
regarding expectations regarding the ability of Galapagos to launch
its first product and timing of such potential launch, and the
expansion of Galapagos’ team and commercial capabilities. Galapagos
cautions the reader that forward-looking statements are not
guarantees of future performance. Forward-looking statements
involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition and
liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or
achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos’ results, performance,
financial condition and liquidity, and the development of the
industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. Among the factors that may
result in differences are that Galapagos may not be able to obtain
regulatory approval for its first commercial product candidate,
that Galapagos may not be able to successfully (or at all) launch
its first product, and Galapagos' reliance on collaborations with
third parties (including its collaboration partner Gilead). A
further list and description of these risks, uncertainties and
other risks can be found in Galapagos’ Securities and Exchange
Commission (SEC) filings and reports, including in Galapagos’ most
recent annual report on Form 20-F filed with the SEC and subsequent
filings and reports filed by Galapagos with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements, unless specifically required by law or regulation.
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Oct 2023 to Oct 2024